Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 1.00 |
| ▸ | DRD3 | P35462 | 20/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188361 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL1842073 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL12661863 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4OPRM1 | |
| Water SCHEMBL1841645 | 0.99 | DRD2 (0.97) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL5177150 | 0.94 | DRD2 (0.88) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4249979 | 0.94 | DRD2 (0.88) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4242439 | 0.94 | DRD2 (0.88) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4238881 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4238880 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4388560 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-20240117303-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | claimed |
| WO-2024019800-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-01-25 | — | — | WO | claimed |
| EP-1848709-B1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | PFIZER LTD (GB) | 2011-05-18 | — | — | EP | claimed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | claimed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | claimed |
| EP-2104503-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2009-09-30 | — | — | EP | claimed |
| US-7498329-B2 | Salt form of dopamine agonist | PFIZER INC. (US) | 2009-03-03 | — | — | US | claimed |
| WO-2008087512-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-07-24 | — | — | WO | claimed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | claimed |
| EP-1848709-A1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | Pfizer Limited (GB) | 2007-10-31 | — | — | EP | claimed |
| US-20060183740-A1 | Novel salt form of a dopamine agonist | PFIZER INC | 2006-08-17 | — | — | US | claimed |
| WO-2006082511-A1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | PFIZER LIMITED (GB) | 2006-08-10 | — | — | WO | claimed |
| JP-2006511599-A | — | — | 2006-04-06 | — | — | JP | claimed |
| EP-1572214-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2005-09-14 | — | — | EP | claimed |
| US-20040259874-A1 | Morpholine dopamine agonists | PFIZER INC. | 2004-12-23 | — | — | US | claimed |
| WO-2004052372-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2004-06-24 | — | — | WO | claimed |
| US-12479838-B2 | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2004052372-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479838-B2 | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof | DRD3, ADRB3, VDR | DRD2 7/4885DRD3 1/4885DRD4 17/4885 |
| US-20040259874-A1 | Morpholine dopamine agonists | DBH, OPRM1, OPRD1 | DRD2 16/4885DRD3 35/4885DRD4 50/4885 |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | OPRL1, OPRD1, OPRK1 | DRD2 13/4885DRD3 26/4885DRD4 37/4885 |
| US-20060183740-A1 | Novel salt form of a dopamine agonist | SLC6A3, CHRNA5, TACR2 | DRD2 11/4885DRD3 48/4885DRD4 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.